Intestinal bacteria may protect against diabetes

April 11, 2017

A high concentration of indolepropionic acid in the serum protects against type 2 diabetes, shows a new study from the University of Eastern Finland. Indolepropionic acid is a metabolite produced by intestinal bacteria, and its production is boosted by a fibre-rich diet. According to the researchers, the discovery provides additional insight into the role of intestinal bacteria in the interplay between diet, metabolism and health.

The findings were published in Scientific Reports. The study was carried out in the LC-MS Metabolomics Centre of the University of Eastern Finland together with a large number of partners from Finnish and Swedish research institutes.

The study compared two groups participating in the Finnish Diabetes Prevention Study, DPS. At the onset of the study, all participants were overweight and had impaired glucose tolerance. The researchers investigated the serum metabolite profile of 200 participants with impaired glucose tolerance, who either developed type 2 diabetes within the first 5 years, or did not convert to type 2 diabetes within a 15-year follow-up. The differences between the groups were analysed by non-targeted metabolomics analysis. Instead of focusing on just a few pre-defined markers, metabolomics analysis allows for the determination of the study participants' metabolic profile, i.e. the concentrations of several metabolites.

The greatest differences in the metabolic profiles of those who developed type 2 diabetes and those who didn't were observed in the concentrations of indolepropionic acid and certain lipid metabolites.

A high concentration of indolepropionic acid in the serum was discovered to protect against diabetes. Indolepropionic acid is a produced by . A diet rich in whole grain products and dietary fibre increased the indolepropionic acid concentration.  A higher concentration of indolepropionic acid also seemed to promote insulin secretion by pancreatic beta cells, which may explain the protective effect.

In addition to the DPS data, the association of indolepropionic acid with the risk of diabetes was also studied in two other population-based datasets: in the Finnish Metabolic Syndrome In Men Study, METSIM, and in the Swedish Västerbotten Intervention Project, VIP. In these datasets too, indolepropionic acid was discovered to protect against diabetes.

The study also identified several new lipid metabolites whose high concentrations were associated with improved insulin resistance and reduced risk of diabetes. The concentrations of these metabolites were also associated with dietary fat: the lower the amount of saturated fat in the diet, the higher the concentrations of these metabolites.  Similarly to indolepropionic acid, high concentrations of these lipid metabolites also seemed to protect against low-grade inflammation.

"Earlier studies, too, have linked intestinal with the risk of disease in overweight people. Our findings suggest that indolepropionic may be one factor that mediates the protective effect of diet and intestinal bacteria," Academy Research Fellow Kati Hanhineva from the University of Eastern Finland says.

A direct identification of intestinal bacteria is a complex process, which is why identifying the metabolites produced by intestinal bacteria may be a more feasible method for analysing the role of intestinal bacteria in the pathogenesis of, for example, diabetes.

The Finnish Diabetes Prevention Study was the first randomised, controlled lifestyle intervention study to show that in persons with impaired glucose tolerance, type 2 can be prevented by lifestyle changes. The most important lifestyle changes included weight loss, more exercise and dietary adjustments to include more whole grain products, fruits and vegetables.

Explore further: High serum omega-6 polyunsaturated fatty acid concentrations linked to lower risk of type 2 diabetes

More information: Vanessa D. de Mello et al. Indolepropionic acid and novel lipid metabolites are associated with a lower risk of type 2 diabetes in the Finnish Diabetes Prevention Study, Scientific Reports (2017). DOI: 10.1038/srep46337

Related Stories

High serum omega-6 polyunsaturated fatty acid concentrations linked to lower risk of type 2 diabetes

March 24, 2016
A new study from the University of Eastern Finland shows that high serum omega-6 polyunsaturated fatty acid concentrations are linked to a significantly reduced risk of type 2 diabetes. The findings were published in the ...

Urine metabolites may help predict which obese teens will develop diabetes

April 4, 2017
Researchers have discovered a unique metabolic "signature" in the urine of diabetic, obese black teenagers that they say may become a way to predict the development of type 2 diabetes in people at risk. They will present ...

Fish derived serum omega-3 fatty acids help reduce the risk of type 2 diabetes

January 14, 2014
High concentrations of serum long-chain omega-3 fatty acids may help reduce the risk of type 2 diabetes, according to a University of Eastern Finland study published recently in Diabetes Care. The sources of these fatty acids ...

Even mildly excessive body iron stores increase the risk of type 2 diabetes

November 30, 2016
Even mildly elevated body iron contributes to the prevalence and incidence of type 2 diabetes, according to research from the University of Eastern Finland. Excess body iron accumulation is a known risk factor of type 2 diabetes ...

Altered purine metabolism linked to depression

May 17, 2016
People suffering from major depressive disorder may have altered purine metabolism, according to a new study from the University of Eastern Finland and Kuopio University Hospital. Purines are nitrogenous compounds that serve ...

Metabolites linked to renal decline, time to ESRD in T1DM

January 19, 2017
(HealthDay)—Serum levels of seven modified metabolites are associated with renal function decline and time to end-stage renal disease (ESRD) among patients with type 1 diabetes (T1D), according to a study published online ...

Recommended for you

Diabetes pill might replace injection to control blood sugar

October 17, 2017
(HealthDay)— An injectable class of diabetes medication—called glucagon-like peptide-1 or GLP-1—might one day be available in pill form, research suggests.

Skimping on sleep may contribute to gestational diabetes

October 17, 2017
The amount of time spent sleeping in the United States has dropped significantly in the past twenty years with almost a quarter of women and 16 percent of men experiencing insufficient sleep. Now, a new study has found that ...

Artificial pancreas performs well in clinical trial

October 16, 2017
During more than 60,000 hours of combined use of a novel artificial pancreas system, participants in a 12-week, multi-site clinical trial showed significant improvements in two key measures of well-being in people living ...

Omega-6 fats may help prevent type 2 diabetes

October 11, 2017
The risk of developing type 2 diabetes could be significantly reduced by eating a diet rich in omega-6 polyunsaturated fats, a new study suggests.

Where there's type 1 diabetes, celiac disease may follow

October 10, 2017
(HealthDay)—Parents of young children with type 1 diabetes need to be on the lookout for symptoms of another autoimmune condition—celiac disease, new research suggests.

Type 1 diabetes and the microbiota—MAIT cells as biomarkers and new therapeutic targets

October 10, 2017
Together with colleagues from AP-HP Necker–Enfants Malades Hospital in Paris, scientists from the Cochin Institute (CNRS / INSERM / Paris Descartes University) have discovered that the onset of type 1 diabetes is preceded ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.